ALK and non-small cell lung carcinoma: Alectinib was licensed by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2015 for the management of anaplastic lymphoma kinase-positive progressive non-small cell lung cancer (NSCLC).